Document is current
Any future updates will be listed below
-
Authors
Visaria, Aayush
McDonald, William
Mancini, John
Ambrosy, Andrew P.
Kwak, Min Ji
Hashemi, Ashkan
Lachs, Mark S.
Zullo, Andrew R.
Safford, Monika
Levitan, Emily B.
Goyal, Parag https://orcid.org/0000-0001-7474-3737
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), National Institutes of Health, and the Department of Health and Human Services (U01 NS041588)
National Heart, Lung, and Blood Institute (R01HL080477)
National Institute on Aging (R03AG056446)
- License Information
-
More Information
Article History
Accepted: 17 November 2024
First Online: 27 December 2024
Declarations
:
: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. Additional funding was provided by National Heart, Lung, and Blood Institute (NHLBI) grant R01HL080477 and NIA grant R03AG056446.
: P.G. is supported by National Institute on Aging grants K76AG064428, R21AG077092, and R01AG085420; was a member of the Junior Investigator Intensive Program of the US Deprescribing Research Network and is supported by a US Deprescribing Research Pilot Grant funded by the National Institute on Aging (R24AG064025); reports personal fees from Agepha Pharma, Akros Pharma, Axon therapies, and Sensorum Health; and has received personal fees for medicolegal consulting and expert testimony related to HF. A.P.A. has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159), the American Heart Association (2nd 305 Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Edwards Lifesciences LLC, Esperion Therapeutics, Inc., and Novartis. E.B.L. has received research funding from Amgen, Inc, and personal fees from University of Pittsburgh for serving on a data safety and monitoring board. Aayush Visaria, William McDonald, John Mancini, Min Ji Kwak, Ashkan Hashemi, Mark S. Lachs, and Andrew R. Zullo declare that they have no potential conflicts of interest that might be relevant to this work.
: This retrospective study was approved by the Weill Cornell Institutional Review Board.
: All participants provided written informed consent.
: Not applicable.
: The data that support the findings of this study are available from the REGARDS-MI substudy (Parent REGARDS Study Data Access: , REGARDS-MI: ), but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the corresponding author.
: Not applicable.
: A.V.: analysis, data curation, methodology, software, visualization, writing, reviewing and editing; W.M.: analysis, visualization, writing, reviewing and editing; J.M.: conceptualization, validation, reviewing and editing; A.A.: validation, reviewing and editing, investigation; M.J.K.: analysis, investigation, methodology, reviewing and editing; A.H.: data curation, analysis, project administration, reviewing and editing; M.L.: conceptualization, methodology, reviewing and editing; A.Z.: methodology, validation, reviewing and editing; M.S.: funding acquisition, methodology, resources, supervision, reviewing and editing; E.L.: methodology, resources, supervision, reviewing and editing; and P.G.: conceptualization, data curation, funding acquisition, investigation, methodology, resources, writing, reviewing and editing.
